Pembrolizumab for Edema
Phase-Based Progress Estimates
Effectiveness
Safety
Edema+12 More
Pembrolizumab - BiologicalEligibility
18+
All Sexes
What conditions do you have?
Select
Eligibility
18+
All Sexes
What conditions do you have?
Select
Study Summary
This trial will study how well pembrolizumab works in treating metastatic or recurrent inflammatory breast cancer or triple-negative breast cancer.
Eligible Conditions
- Edema
- Estrogen Receptors
- Recurrent Inflammatory Breast Carcinoma
- HER2/Neu Negative
- Peau d'Orange
- Inflammatory Breast Carcinoma
- Receptors, Progesterone
- Erythema
- Triple Negative Breast Carcinoma
Treatment Effectiveness
Effectiveness Progress
Study Objectives
1 Primary · 3 Secondary · Reporting Duration: Up to 3 months post-treatment
Baseline
Biomarker analyses
Month 3
Disease control survival
Overall survival time
Rate of disease control
Trial Safety
Safety Progress
This is further along than 68% of similar trials
Side Effects for
Pembrolizumab Second Course
100%Urinary tract infection
100%Parkinsonism
100%Inappropriate antidiuretic hormone secretion
Trial Design
1 Treatment Group
Treatment (pembrolizumab)
1 of 1
Experimental Treatment
35 Total Participants · 1 Treatment Group
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Treatment (pembrolizumab)Experimental Group · 2 Interventions: Pembrolizumab, Laboratory Biomarker Analysis · Intervention Types: Biological, Other
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pembrolizumab
FDA approved
Trial Logistics
Trial Timeline
Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: up to 3 months post-treatment
Who is running the clinical trial?
M.D. Anderson Cancer CenterLead Sponsor
2,779 Previous Clinical Trials
1,784,736 Total Patients Enrolled
1 Trials studying Edema
42 Patients Enrolled for Edema
National Cancer Institute (NCI)NIH
12,991 Previous Clinical Trials
41,298,458 Total Patients Enrolled
1 Trials studying Edema
42 Patients Enrolled for Edema
Bora LimPrincipal InvestigatorM.D. Anderson Cancer Center
1 Previous Clinical Trials
95 Total Patients Enrolled
Eligibility Criteria
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “yes” if the following statements are true for you:You have been treated for stage IV or recurrent disease.
You have a performance status of 0-1 on the ECOG performance scale.
You have HER2 negative by IHC or FISH if performed; or HER2 positive by IHC or FISH if not performed.
You have a hemoglobin level of at least 9 g/dL.
Creatinine levels are below the upper limit of normal.
About The Reviewer
Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.
Top Oncology Trials
Top Clinical Trials in Cities
Relevant Clinical Trials
Unbiased Results
We believe in providing patients with all the options.Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.Back to top
Conditions
Cancer Related
Treatments